Australia's largest stock trading and investment forum Australia's #1 stock forum

KZA

0.00%

8.0¢ kazia therapeutics limited

2019 San Antonio Breast Cancer Symposium, page-56

First 56 Last

Share
Profile

Follow
cane7

4,133 Posts.

275

11/12/19

14:54

Post #: 41913012
Share

Originally posted by rikki: ↑

JG is worth every penny. None of this is happy coincidence this is a strategy rolling out before our eyes.

He did say the previous CR may well be the last... they also said there’s a high bar to meet for a partner to come onboard.

Comments have been made clearly and matter of factly

I’d say for partners and investors - things are moving with or without you it’s pushing forward so if you want to be involved... you need to be holding.

No one saw this coming as an option for trial direction - not a single word not a single inkling was expressed for this to be an option. There was the never ending story of how expensive trials are generically and how there can’t be anything of value due to the MC at 46mil... all twoddle.

When a deal is finalised we will find out about it - there will not be any warning or chance to jump onboard etc... this is as it should be, you believe and you are in and part of the deal.

Some seem to think they will wait for the right time and jump in for a quick return this won’t happen you will miss out - this is a stock for investors not for the short term gambler. The company is actively working in a way to maintain value for investors as a priority.

Most likely there will be discussions as usual and out of the blue we will go to a halt and a deal will be in the rearview mirror... there will not be endless announcements of entering into discussions with party a b c etc as per other biotechs.

Very happy to hold this stock it’s the most interesting on the ASX as far as I’m concerned

Expand

You are right rikki, it will happen in a flash, deal done with partner, trading halt, then you would have to pay a hell of lot more to get in. way to go!!

KZA Price at posting: 66.5¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BUX

Buxton projects new graphite province discovery at WA Narryer play

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

There are more pages in this discussion • 5 more messages in this thread...

First 56 Last

Add KZA (ASX) to my watchlist

2019 San Antonio Breast Cancer Symposium, page-56

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News